TY - JOUR
T1 - Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort
AU - Kopplin, Noa
AU - Garcia, Angie
AU - Reczek, Annika
AU - Wilkinson, Kate
AU - Yekkaluri, Sruthi
AU - Murphy, Caitlin C.
AU - Tiro, Jasmin
AU - Muthukumar, Alagar R.
AU - Masica, Andrew
AU - Singal, Amit G.
N1 - Publisher Copyright:
© 2023 Kopplin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/9
Y1 - 2023/9
N2 - Background Coronavirus disease 2019 (COVID-19) infection invokes variable immune responses and poses a risk of post-acute sequelae SARS-CoV-2 infection (PASC) symptoms; however, most data on natural history are derived from patients with severe infection. Further data are needed among patients with mild infection, who comprise most cases. Methods The Dallas Fort-Worth (DFW) COVID-19 Prevalence Study included 21,597 community-dwelling adults (ages 18–89) who underwent COVID-19 PCR and anti-nucleocapsid antibody testing between July 2020 and March 2021. We invited participants with positive COVID-19 results (cases) and a subset with negative results (controls), matched on age, sex, race/ethnicity, and ZIP code, to complete a follow-up questionnaire for PASC symptoms and repeat anti-nucleocapsid testing, and anti-spike antibody testing between July and December 2021. Results Of 3,917 adults invited to participate, 2260 (57.7%) completed the questionnaire–1150 cases and 1110 controls. Persistent symptoms were reported in 21.1% of cases, with the most common being shortness of breath, fatigue, and loss of taste or smell. Among 292 cases with asymptomatic infection, >15% reported new fatigue and 8–10% reported new loss of taste/smell, myalgias, or headache. Median anti-nucleocapsid levels in cases decreased from 3.5U to 0.7U over a median follow-up of 8.6 months. Anti-spike antibody levels at 6–7 months post-vaccination in cases were similar to that of controls. Conclusions More than 1 in 5 patients with COVID-19 infection, including those with mild infection, reported persistent symptoms during follow-up. Both nucleocapsid and spike protein antibody levels decreased within six months following a COVID-19 infection and vaccination.
AB - Background Coronavirus disease 2019 (COVID-19) infection invokes variable immune responses and poses a risk of post-acute sequelae SARS-CoV-2 infection (PASC) symptoms; however, most data on natural history are derived from patients with severe infection. Further data are needed among patients with mild infection, who comprise most cases. Methods The Dallas Fort-Worth (DFW) COVID-19 Prevalence Study included 21,597 community-dwelling adults (ages 18–89) who underwent COVID-19 PCR and anti-nucleocapsid antibody testing between July 2020 and March 2021. We invited participants with positive COVID-19 results (cases) and a subset with negative results (controls), matched on age, sex, race/ethnicity, and ZIP code, to complete a follow-up questionnaire for PASC symptoms and repeat anti-nucleocapsid testing, and anti-spike antibody testing between July and December 2021. Results Of 3,917 adults invited to participate, 2260 (57.7%) completed the questionnaire–1150 cases and 1110 controls. Persistent symptoms were reported in 21.1% of cases, with the most common being shortness of breath, fatigue, and loss of taste or smell. Among 292 cases with asymptomatic infection, >15% reported new fatigue and 8–10% reported new loss of taste/smell, myalgias, or headache. Median anti-nucleocapsid levels in cases decreased from 3.5U to 0.7U over a median follow-up of 8.6 months. Anti-spike antibody levels at 6–7 months post-vaccination in cases were similar to that of controls. Conclusions More than 1 in 5 patients with COVID-19 infection, including those with mild infection, reported persistent symptoms during follow-up. Both nucleocapsid and spike protein antibody levels decreased within six months following a COVID-19 infection and vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85170344561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170344561&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0291259
DO - 10.1371/journal.pone.0291259
M3 - Article
C2 - 37682916
AN - SCOPUS:85170344561
SN - 1932-6203
VL - 18
JO - PloS one
JF - PloS one
IS - 9 September
M1 - e0291259
ER -